医学
肝细胞癌
丙型肝炎
丙型肝炎病毒
肝硬化
入射(几何)
人口
传输(电信)
内科学
肝炎
肝病
儿科
病毒学
环境卫生
病毒
工程类
物理
光学
电气工程
作者
C. Wendy Spearman,Geoffrey Dusheiko,Margaret Hellard,Mark Sonderup
出处
期刊:The Lancet
[Elsevier]
日期:2019-10-01
卷期号:394 (10207): 1451-1466
被引量:302
标识
DOI:10.1016/s0140-6736(19)32320-7
摘要
Hepatitis C is a global health problem, and an estimated 71·1 million individuals are chronically infected with hepatitis C virus (HCV). The global incidence of HCV was 23·7 cases per 100 000 population (95% uncertainty interval 21·3–28·7) in 2015, with an estimated 1·75 million new HCV infections diagnosed in 2015. Globally, the most common infections are with HCV genotypes 1 (44% of cases), 3 (25% of cases), and 4 (15% of cases). HCV transmission is most commonly associated with direct percutaneous exposure to blood, via blood transfusions, health-care-related injections, and injecting drug use. Key high-risk populations include people who inject drugs, men who have sex with men, and prisoners. Approximately 10–20% of individuals who are chronically infected with HCV develop complications, such as cirrhosis, liver failure, and hepatocellular carcinoma over a period of 20–30 years. Direct-acting antiviral therapy is now curative, but it is estimated that only 20% of individuals with hepatitis C know their diagnosis, and only 15% of those with known hepatitis C have been treated. Increased diagnosis and linkage to care through universal access to affordable point-of-care diagnostics and pangenotypic direct-acting antiviral therapy is essential to achieve the WHO 2030 elimination targets.
科研通智能强力驱动
Strongly Powered by AbleSci AI